378P - Preclinical characterization of IMAB362 for the treatment of gastric carcinoma

Autor: Mitnacht-Kraus, R. ¹, Kreuzberg, M. ¹, Utsch, M. ¹, Sahin, U. ², Türeci, Ö. ¹

Publikováno v: In Annals of Oncology September 2017 28 Supplement 5:v126-v126

Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Autor: Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan., Xu RH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Ajani JA; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Moran D; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Guerrero A; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Li R; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Pavese J; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Matsangou M; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Bhattacharya P; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Ueno Y; Astellas Pharma Inc., Tokyo, Japan., Wang X; Astellas Pharma Global Development, Inc., Northbrook, IL, USA., Shah MA; Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York City, NY, USA. mas9313@med.cornell.edu.

Publikováno v: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2024 Sep; Vol. 27 (5), pp. 1058-1068. Date of Electronic Publication: 2024 Jul 02.

Characterization of zolbetuximab in pancreatic cancer models.

Autor: Türeci Ӧ; Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany., Mitnacht-Kraus R; Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany., Wöll S; Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany., Yamada T; Astellas Pharma, Inc., Tokyo, Japan., Sahin U; TRON - Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Publikováno v: Oncoimmunology [Oncoimmunology] 2018 Nov 10; Vol. 8 (1), pp. e1523096. Date of Electronic Publication: 2018 Nov 10 (Print Publication: 2019).

TGF-β1, pSmad-2/3, Smad-7, and β-Catenin Are Augmented in the Pulmonary Arteries from Patients with Idiopathic Pulmonary Fibrosis (IPF): Role in Driving Endothelial-to-Mesenchymal Transition (EndMT).

Autor: Gaikwad, Archana Vijay^1,2 (AUTHOR), Eapen, Mathew Suji^1,2 (AUTHOR), Dey, Surajit¹ (AUTHOR), Bhattarai, Prem¹ (AUTHOR), Shahzad, Affan Mahmood¹ (AUTHOR), Chia, Collin^1,3,4 (AUTHOR), Jaffar, Jade^5,6 (AUTHOR), Westall, Glen^5,6 (AUTHOR), Sutherland, Darren^7,8 (AUTHOR), Singhera, Gurpreet Kaur^7,8 (AUTHOR), Hackett, Tillie-Louise^7,8 (AUTHOR), Lu, Wenying^1,2,3 (AUTHOR), Sohal, Sukhwinder Singh^1,2,3 (AUTHOR) sukhwinder.sohal@utas.edu.au

Publikováno v: Journal of Clinical Medicine. Feb2024, Vol. 13 Issue 4, p1160. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.